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Hyaluronan (HA) is one of the most prevalent glycosamino-
glycans of the vascular extracellular matrix (ECM). Abnormal
HA accumulation within blood vessel walls is associated with
tissue inflammation and is prominent in most vascular patho-
logical conditions such as atherosclerosis and restenosis. Hyalu-
ronan synthase 2 (HAS2) is the main hyaluronan synthase
enzyme involved inHA synthesis anduses cytosolicUDP-glucu-
ronic acid and UDP-GlcNAc as substrates. The synthesis of
UDP-glucuronic acid can alter the NAD/NADH ratio via the
enzyme UDP-glucose dehydrogenase, which oxidizes the alco-
hol group at C6 to the COO group. Here, we show that HAS2
expression can be modulated by sirtuin 1 (SIRT1), the master
metabolic sensor of the cell, belonging to the class of NAD-de-
pendent deacetylases. Our results revealed the following. 1)
Treatments of human aortic smooth muscle cells (AoSMCs)
with SIRT1 activators (SRT1720 and resveratrol) inhibit both
HAS2 expression and accumulation of pericellular HA coats. 2)
Tumor necrosis factor  (TNF) induced HA-mediated mono-
cyte adhesion andAoSMCmigration, whereas SIRT1 activation
prevented immune cell recruitment and cell motility by reduc-
ing the expression levels of the receptor forHA-mediatedmotil-
ity, RHAMM, and the HA-binding protein TNF-stimulated
gene 6 protein (TSG6). 3) SIRT1 activation prevented nuclear
translocation of NF-B (p65), which, in turn, reduced the levels
of HAS2–AS1, a long-noncoding RNA that epigenetically con-
trols HAS2 mRNA expression. In conclusion, we demonstrate
that both HAS2 expression and HA accumulation by AoSMCs
are down-regulated by the metabolic sensor SIRT1.
Hyaluronan (HA)5 is a ubiquitous glycosaminoglycan (GAG)
that is one of the main components of extracellular matrices
(ECMs) (1). It is composed of the repeating disaccharide D-glu-
curonic acid (GlcNAc), and differently from other GAGs, HA
does not possess any chemical modifications (sulfation, acety-
lation, and epimerization), lacks a protein anchor, and can
reach millions of Da of molecular mass (2). In addition to its
well-known physical–chemical properties, HA has a critical
role in the control of cell behavior, including proliferation,
motility, differentiation, and survival (3–9) through the inter-
action with several receptors, including CD44, RHAMM, and
TLR2/4 that are able to trigger specific signaling cascades (10).
Moreover, HA can modulate immune systems, and it is gener-
ally accepted that low and high molecular mass HA have pro-
and anti-inflammatory properties, respectively (11). Further-
more, heavy chains (HC) of inter--trypsin inhibitor can be
covalently bound to HA, forming HC–HA matrices, through
the action of tumor necrosis factor-inducible gene 6 protein
(TSG6) (12, 13). Although HC–HA has an essential physiolog-
ical role during mammalian oocyte maturation (14), in patho-
logical conditions monocytes interact with HC–HA matrices
via cell-surface CD44, thereby contributing to immune cells’
recruitment to the site of inflammation (15). As HA regulates a
variety of cellular phenomena, it is not surprising that it has
critical roles in several pathologies, including cancers (16, 17),
vascular diseases (18), diabetes (19), and respiratory diseases
(20) that are the first causes of death in Western countries.
In tissues, HA has a rapid turnover, and its synthesis is cata-
lyzed by a family of three isoenzymes HAS1, -2, and -3. Con-
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versely, its degradation is due to different hyaluronidases
(HYAL1–6) that work at acidic pH, and other related enzymes
(i.e. TMEM2 and KIAA1199) that have an optimumpH around
the physiological value (21, 22). HASes are very unusual pro-
teins as they are transported to the plasma membrane where
they are able to form homo- and heterodimers and are acti-
vated to extrude the nascent HA chain into the extracellular
space (23). In physiological conditions, HAS1 andHAS2 syn-
thesize HA polymers of high molecular mass, whereas HAS3
synthesizes shorter HA polymers (24), and the production of
low molecular mass HA can be obtained by the action of
degrading enzymes as well as by oxidative stress or UV light
(25, 26). Interestingly, the stoichiometry of the cytosolic
UDP substrates has a critical role to define HA polymer
length, and the C-terminal region of HASes appears to have
regulatory functions (27).
At the cellular level, the specific role of each HAS isoenzyme
is still unknown, but among the three HASes, HAS2 is consid-
ered the most important one. Its genetic deletion leads to early
embryonic death due to cardiac defects, whereas the HAS1 and
HAS3 knockouts are viable and fertile (28). Interestingly, HAS2
activity is strictly regulated by several mechanisms that can
act both at the protein level (as phosphorylation, O-linked
N-acetylglucosamine, and ubiquitination) (29) as well as at the
genetic level (30). Another critical point to consider in HAS2
regulation is its intracellular trafficking, as has recently been
shown by Melero-Fernandez de Mera et al. (31). Several tran-
scription factors are known to modulate HAS2 in response to
growth factors, hormones, and cytokines (30). Recently, it has
been described that HAS2 antisense 1 (HAS2–AS1), a long-
noncoding RNA that belongs to the class of natural antisense
transcripts, is able to control HAS2 epigenetically (32) and that
HAS2–AS1 is able to alter the chromatin structure around the
HAS2 promoter inducing HAS2 transcription in vascular
smooth muscle cells (33) and tumor cells (34, 35).
HAS substrates are cytosolic UDP-GlcNAc and UDP-glucu-
ronic acid (UDP-GlcUA), which are synthesized by UDP-
glucose (UDP-Glc) dehydrogenase (UGDH). We previously
showed that UGDH overexpression and silencing led to an
increase and a decrease of the HAS2 transcript, respectively,
suggesting a regulatory mechanism involving cytosolic UDP-
Glc that is able to coordinate the expression of HAS2 with the
presence of its substrate (36). Interestingly, UGDH catalyzes
the double oxidation of the C6 of UDP-Glc converting the alco-
holic group into a carboxylic group by using two molecules of
the cofactor NAD that are converted to NADH. Therefore,
the synthesis of UDP-GlcUA is able to influence the NAD/
NADH ratio (32).
NAD controls the activity of several enzymes, including
sirtuins (37). Sirtuin 1 (SIRT1) belongs to the family of NAD-
dependent deacetylases, and its protective role in cancers, vas-
cular diseases, and aging is well-known (38–40). It is generally
accepted that when nutrients are not limiting, NAD levels are
low, althoughwhen there is nutrient shortage or caloric restric-
tion NAD increases and activates sirtuins (41). SIRT1 is
located in both the nucleus, where it can deacetylate histones,
and in the cytosol, where it can deacetylate several proteins,
including RelA/p65 that inhibits NF-B activation (42, 43).
Interestingly, SIRT1 controls critical aspects of vascular SMC
biology and pathology, including differentiation (44) and calci-
fication (45).
AsHAS2 is a critical enzyme involved in atherosclerosis with
vessel thickening and its transcription is regulated by NF-B
(46), this study investigated whether HAS2 expression could be
regulated by SIRT1 in human aortic smooth muscle cells and
whether SIRT1 could control pro-atherogenic behavior of
AoSMCs after TNF proinflammatory treatments.
Results
HAS2 is the main enzyme involved in HA synthesis in AoSMCs
AoSMCs generally produce high amounts of HA, which is
the main component of vascular ECM, along with type I and III
fibrillar collagen, elastin, and versican (47). Gene expression
analysis of AoSMCs showed that HAS2 is the prevalent HAS
isoformwithmRNA levels 30 times higher thanHAS3, whereas
HAS1 expression was not detected (Fig. 1A). To determine the
contribution of each isoform on HA synthesis, AoSMCs were
nucleofectedwith 50nM siRNAagainst the threeHAS isoforms,
and after 48 h of incubation, the amounts of HA secreted in cell
culture media were analyzed by PAGEFS (Fig. 1B) (48). The
electrophoretic analysis showed that the silencing of HAS2
caused a 70% decrease in the levels of unsaturated HA disac-
charides (HA), whereas the knockdown of HAS3 and HAS1
Figure 1. HASes expression and HA synthesis in AoSMCs. A, quantitative
RT-PCR analyses are shown for basal HASes mRNA levels in AoSMCs. Data are
expressed as mean S.E. of three independent experiments. ***, p 0.001;
N.D., not determined. B, image is shown of a representative PAGEFS analysis
ofHA andCS-0S disaccharides in the culture medium of AoSMCs after the
silencing of HASes. AoSMCs were transfected with 50 nM of scrambled siRNA
(siScrambled) or transfected with 50 nM of each HAS siRNA. After 48 h, cell
culture media were collected, and HA and CS-0S were analyzed by
PAGEFS. The quantification of the bands was done by measuring their optical
density using the ImageJ software.
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reduced HA disaccharides amount by only 5 and 10%, respec-
tively, providing evidence for a pivotal role of HAS2 in AoSMC
HA synthesis. No effects were detected on the band corre-
sponding to the unsaturated chondroitin 0–sulfate disaccha-
ride (CS-0S). Considering the importance of HAS2 with
respect to HAS1 and HAS3, our study focused primarily on
HAS2 expression.
SIRT1 activators inhibit HAS2 expression and reduce
pericellular HA matrix
To investigate the effects of SIRT1 on HAS2 expression, we
treated AoSMCs for 24 h with resveratrol (RESV), an antioxi-
dant polyphenol nonflavonoid compound that is able to indi-
rectly activate SIRT1 (49), and with SRT1720, a selective syn-
thetic SIRT1 activator (50, 51). The exposure to SRT1720
showed a dose-response effect on HAS2 mRNA expression,
with a stronger inhibitory effect at the concentration of 1 M
(Fig. 2A). A similar trendwas observedwith increasing amounts
of RESV, where the concentration of 100 M was the most effi-
cient to decrease HAS2 mRNA levels to near zero (Fig. 2B).
Considering the effects on HAS2 transcript, all the following
experiments used 1 M SRT1720 and 100 M RESV. At these
concentrations, both the compounds did not show any effects
on cells viability (data not shown). The effects of SRT1720 and
RESVwere specific onHAS2mRNA as these compounds failed
to modulate HAS3 transcript levels (Fig. 2C). As HAS2 expres-
sion can be regulated by HAS2–AS1, we found that SRT1720
and RESV were also able to inhibit the expression of HAS2–
AS1 by 85% (SRT1720) and 80% (RESV) (Fig. 2D), confirming
the co-regulation of HAS2 and HAS2–AS1 in these cells (33).
Western blotting experiments showed that SRT1720 reduced
HAS2 protein 30% after 24 and 48 h, whereas RESV did not
Figure 2. Effects of SRT1720 and RESV on HAS2 expression and HA production. Quantitative RT-PCR analyses are shown for HAS2 expression in AoSMCs
treated for 24 h with 0.1 or 1 M SRT1720 (A) and 1, 10, or 100 M RESV (B). Data are reported as mean S.E. of three independent experiments. ***, p 0.001.
Quantitative RT-PCR of HAS3 (C) and HAS2–AS1 (D) expression after AoSMCs were treated with 1 M SRT1720 or 100 M RESV for 24 h. Data are reported as
mean S.E. of three independent experiments. ***, p 0.001. Western blotting analyses and relative quantification (bar graph) are show for a 30-g protein
extract from AoSMCs treated with 1 M SRT1720 or 100 M RESV for 24 h (E) and for 48 h (F). The images report a representative immunoblot for HAS2 and
GAPDH upon the treatment with 1 M SRT1720 or 100 M RESV. Numbers represent the molecular mass of the relative protein expressed in kDa. The analysis
was performed measuring the optical density of the bands, and values are expressed as percentage variation of the control  S.E. of four independent
experiments. **, p 0.01, and ***, p 0.001. G, quantification of HA amounts determined by ELISA-like assays is shown for AoSMCs cultured in media after a
24-h treatment with 1 M SRT1720 or 100 M RESV. Results are represented as nanograms of HA normalized to total micrograms of RNA of three independent
experiments. H, pericellular coat areas were determined by particle exclusion assay. As a control, AoSMCs were incubated for 1 h with 2 units/ml of HYAL from
S. hyaluroliticus. Results are expressed as the ratio between the area of the ECM and the area of the cells. Experiments were conducted four times, and HA
pericellular coat values are reported as mean S.E. ***, p 0.001; CNTR, control.
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have any effects on HAS2 protein levels at 24 and 48 h of treat-
ment (Fig. 2, E and F).
As HAS2 is the most important enzyme in AoSMCs for the
production of HA, we measured HA levels after the treat-
ment with SRT1720 and RESV and did not find significant
changes in the levels of secreted HA in the culture medium
(Fig. 2G). However, both SRT1720 and RESV caused signif-
icant reductions of the pericellular coats of AoSMCs (Fig. 2H
and in Fig. S1) comparable with the treatment with HYAL,
suggesting that the pericellular matrix of AoSMCs is pre-
dominantly composed of HA, which can be stimulated by the
two SIRT1 activators.
SIRT1 regulates HAS2 expression in AoSMCs
To confirm whether SIRT1 could regulate HAS2 expression,
we transfected AoSMCs with an siRNA against SIRT1, which
silenced SIRT160% (Fig. 3A). The silencing of SIRT1 caused
an60% increment of HAS2mRNA expressionwith respect to
the control (Fig. 3B). Moreover, Western blot analysis using a
HAS2-specific polyclonal antibody showed the presence of an
immunoreactive band at 63 kDa, and the relative densitometric
quantification revealed a 30% increase of the HAS2 protein lev-
els (Fig. 3C), indicating that SIRT1 was able to regulate both
HAS2 mRNA and protein expressions.
SIRT1 activators protect AoSMCs from inflammation
Recent studies have shown that SRT1720 and RESV have
anti-inflammatory effects and exert a protective role in athero-
sclerosis (52, 53). To mimic the inflammatory status of
AoSMCs during atherosclerosis, we treated the cells with
TNF, a pleiotropic cytokine that mediates vascular SMC
migration and proliferation (54, 55). Fig. 4A shows that stimu-
lation with 0.1g/ml TNF greatly increased theHAS2mRNA
level. Interestingly, the treatment of SRT1720 or RESV together
with TNF restored HAS2 mRNA almost to control levels,
indicating the ability of SIRT1 to modulate HAS2 expression
and confirming the powerful anti-inflammatory effect of the
compounds used. As inflammation can inducemonocyte bind-
Figure 3. SIRT1 regulates HAS2 expression in AoSMCs. Quantitative RT-
PCR analyses show SIRT1-silencing efficiency (A) and HAS2 mRNA expression
after transfection of 100 nM siRNA against SIRT1 in AoSMCs (B). Experiments
were done three times and are displayed as mean S.E. *, p 0.05, and ***,
p  0.001. C, HAS2 protein levels were analyzed by Western blottings of
AoSMC lysates after 100 nM siSIRT1 transfection, and bars show relative quan-
tification. Images represent one experimental replicate of the immunoreac-
tive bands for HAS2 and -tubulin in the different experimental conditions.
Numbers on the margin of the blots represent the molecular masses expressed
in kDa. The analysis was performed measuring the optical density of the
bands, and values are expressed as percentage variation of the control of four
independent experiments. **, p 0.01.
Figure 4. Effects of SIRT1 activators on TNF-induced inflammation. A,
HAS2 mRNA levels were determined by quantitative RT-PCR in AoSMCs
treated for 24 h with 0.1 g/ml TNF alone or in combination with 1 M
SRT1720 or 100 M RESV. Experiments were conducted five times, and data
are represented as gene relative expression S.E. *, p 0.05; **, p 0.01. B,
U937 monocyte adhesion assays were performed on AoSMCs treated for 24 h
with TNF alone or in combination with 1 M SRT1720 or 100 M RESV. Exper-
iments were conducted three times, and data are expressed as percentage of
control S.E. **, p 0.01; ***, p 0.001. C, AoSMC migration was measured
by scratch assay after treatment with 0.1 g/ml TNF alone or in combination
with 1 M SRT1720 or 100 M RESV. Cell migration was calculated by analyz-
ing the scratch area at different time points (0, 3, 6, and 9 h) normalized to the
starting scratched area values. **, p 0.01; ***, p 0.001. D, AoSMC viability
was determined by MTT assay after 24 h of treatment with 0.1 g/ml TNF
alone or with 1 M SRT1720 or 100 M RESV. Values are expressed as mean
S.E. of three independent experiments performed in quadruplicate. CNTR,
control.
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ing to HA (56, 57), we evaluated the ability of U937 monocytes
to bind to HA produced by AoSMCs. The exposure to TNF
enhanced the adhesion of U937 monocytes 60% to AoSMCs
(Fig. 4B and Fig. S3), which was reduced to control levels by
HYAL. Interestingly, the simultaneous treatment of 0.1 g/ml
TNFwith 1MSRT1720 or 100MRESVdecreased the num-
ber of adherentmonocytes below control levels (Fig. 4B and Fig.
S2) similar to the digestionwithHYAL alone. This suggests that
some monocyte binding in the control and the TNF plus
HYAL cultures may be independent of HA.
A critical event during vessel wall thickening is TNF-medi-
ated migration of AoSMCs to neointima (58). We therefore
performed a scratch assay to evaluate the effects of SRT1720
and RESV on AoSMCmotility (Fig. 4C and Fig. S3). The expo-
sure of AoSMCs to 0.1 g/ml TNF significantly increased cell
motility with respect to the control, whereas the simultaneous
treatment with TNF and SRT1720 or RESV reduced the clo-
sure of the scratch, suggesting that such compounds can
directly influence AoSMCmigration counteracting the pro-in-
flammatory stimulus of TNF. However, TNF and the activa-
tors of SIRT1 did not alter AoSMC proliferation and viability
(Fig. 4D).
SIRT1 activators modulate HA receptor expression and
HA-modifying enzymes
HA triggers several cellular responses interactingwith differ-
ent HA receptors as well as with the modifying enzyme TSG6
(15). RHAMM is themain receptor mediating AoSMCmotility
during vascular injury (59). As shown in Fig. 5B, TNF
enhanced the expression of RHAMM, whereas the addition of
SRT1720 and RESV significantly decreased RHAMM mRNA
levels (Fig. 5B). Notably, these treatments did not significantly
change CD44 mRNA expression (Fig. 5A), the main HA recep-
tor involved in the regulation of vascular SMCproliferation and
viability (60).
Furthermore, we studied the expression of TSG6, which
has a critical role in immune cells and HA recognition in
pericellular HC–HA coats (15). Fig. 5C shows that treatment
with 0.1 g/ml TNF induced a 2.5-fold increase of TSG6
mRNA expression, whereas the simultaneous addition of 1
M SRT1720 or 100 M RESV significantly reduced the
TSG6 messenger.
These results suggest that SIRT1 activators modulate the
expression of the critical proteins involved in HA-mediated
motility and inflammation, likely by formation of a monocyte
adhesive HC–HA matrix.
SIRT1 activators reduce natural antisense transcript HAS2–
AS1 expression and inhibit NF-B nuclear translocation
To investigate the molecular mechanism through which
SIRT1 activators inhibit HAS2 expression, we studied HAS2–
AS1, one of the main regulators of HAS2 transcription in
AoSMCs (33). Quantitative RT-PCR analysis demonstrated
that HAS2–AS1 levels increased three times upon the treat-
ment with TNF (Fig. 6A). Interestingly, the simultaneous
treatment with TNF or SRT1720 and RESV significantly
reduced HAS2–AS1 expression (Fig. 6A).
Control experiments were carried out to exclude a possible
involvement of HAS2 in the control of HAS2–AS1 expression.
As shown in Fig. 6B, silencing HAS2 by siRNA nucleofection
did not influence HAS2–AS1 levels. Moreover, HAS2 knock-
down did not affect the up-regulation of HAS2–AS1 caused by
0.1 g/ml TNF treatment (Fig. 6B) thus confirming the criti-
cal role ofHAS2–AS1 in the regulation ofHAS2 expression and
not vice versa.
NF-B is an important mediator of the inflammatory re-
sponses triggered by TNF. The activation of this pathway
involves the translocation of the p65 subunit from the cyto-
plasm to the nucleus and the subsequent transcription of the
target genes (61). To visualize the subcellular localization of
p65, we nucleofected AoSMCs with a plasmid coding for a
GFP–p65 fusion protein. Our results show that the exposure of
AoSMCs to 0.1 g/ml TNF stimulated the translocation of
GFP–p65 from the cytoplasm to the nucleus (Fig. 6C), whereas
the combined treatment with SRT1720 or RESV retained the
subunit in the cytoplasm. These results suggest that the stimu-
lation of SIRT1 can prevent the activation of an NF-B–
signaling pathway.
Control experiments demonstrated that HAS2 silencing
did not affect p65 localization (Fig. S5), whereas greatly
reduced AoSMC migration after the stimulation with 0.1
g/ml TNF confirmed the critical role of HAS2 to sustain
cell motility (Fig. S5).
To verify the pivotal role of NF-B in the regulation of
HAS2–AS1 in vascular cells, we evaluated p65 localization by
treating AoSMCs for 24 h with 10 M PDTC, a selective inhib-
itor of IKB phosphorylation that blocks p65 nuclear translo-
cation (62). Fig. 7A shows that AoSMCs exposed simultane-
ously to PDTC and TNF retained p65 in the cytoplasm.
Moreover, this combined treatment inhibited AoSMC migra-
tion (Fig. S6) and significantly decreased the expression of
HAS2–AS1 and HAS2 compared with stimulation with TNF
alone (Fig. 7, C and D). These data confirm the critical role of
SIRT1 activators in the regulation of a NF-B pathway and
HAS2–AS1 expression.
Figure 5. SIRT1 activatorsmodulate expression of HA receptors andHA-
modifying enzymes. Quantitative RT-PCR experiments show CD44 (A),
RHAMM (B), and TSG6 (C) mRNA levels. Gene expressions were analyzed in
AoSMCs treated for 24 h with 0.1 g/ml TNF alone or with 1 M SRT1720 or
100 M RESV. Data are represented as mean S.E. of four independent exper-
iments. *, p 0.05; **, p 0.01; *** p 0.001; CNTR, control.
SIRT1 reduces HAS2 expression via NF-B and HAS2–AS1
J. Biol. Chem. (2020) 295(11) 3485–3496 3489
Discussion
In this study,we demonstrate a new regulatorymechanismof
HAS2 in vascular SMCs exerted by SIRT1, the yeast sir2 homo-
log that belongs to the class of NAD-dependent deacetylases.
Several studies have shown that the regulation of HA synthesis
and the control of HAS2 activity are influenced at multiple lev-
els, including transcriptional, post-translational, and epigenetic
regulative mechanisms (23). Interestingly, also the availability
of the HA precursor UDP-GluUA is able to influence HA pro-
duction, and the overexpression of UGDH (the enzyme that
converts UDP-Glc into UDP-GlcUA) increased HA levels and
HAS2 expression in AoSMCs (36). From a metabolic point of
view, this reaction is very important, as it requires two mole-
cules of NAD, suggesting that the synthesis of HA can be a
crucial anabolic pathway able to influence the NAD/NADH
ratio. Besides synthesis of GAGs, UDP-GlcUA is fundamental
for other cellular processes like the reaction of hepatic detoxi-
fication (2). Furthermore, the NAD/NADH ratio tightly reg-
ulates SIRT1 activity, as NAD is a critical cofactor for sub-
strate deacetylation. Othermetabolic processes able to strongly
influence this ratio are the mitochondrial -oxidation of fatty
acid, the conversion of pyruvate into lactate catalyzed by the
lactate dehydrogenase, and the NAD salvage pathway (63).
Importantly, the metabolism of HA shares another aspect
with SIRT1 activity, the contrasting action involved in cardio-
vascular diseases. In atherosclerosis, HA exerts a negative role
in the onset and the progression of the disease. Under patho-
logical conditions, the ECMof AoSMCs is altered and ismainly
composed ofHA,which stimulates cell proliferation andmigra-
tion toward the intimal layer, contributing to vessel thickening
(46, 64). Moreover, an overproduction of HA in the genetic
background of the apoE-deficient mouse strain promotes ath-
erosclerosis development in the aorta (64). However, the sys-
temic inhibition of HA synthesis by 4-methylumbelliferone
showed severe damage in the endothelial cell glycocalyx and
promoted the progression of atherosclerosis (65), suggesting
that a minimum amount of HA is necessary to maintain the
structure of cellular glycocalyces. On the contrary, SIRT1 has
been demonstrated to have a protective role in vascular pathol-
ogies as it can inhibit neointima formation, atherosclerosis, and
vascular SMC hypertrophy (38, 66–68). Thompson et al. (69)
showed a significant difference in SIRT1 levels from human
vascular SMCs isolated from occluded arteries with atheroscle-
rotic lesions compared with nonoccluded sections of the same
arteries, confirming that the reduced expression or activity of
SIRT1 is a key point in vascular dysfunction.
To investigate the correlation between HAS2, HA produc-
tion, and SIRT1 activity, we treated AoSMCswith two different
SIRT1 activators, SRT1720 and RESV. Although their mecha-
nism of action is still under debate (70), these compounds have
been shown to activate SIRT1 in in vivo and in vitro models
(71–73) probably acting like allosteric effectors (74, 75). Indeed,
our data show that the exposure of AoSMCs to SRT1720 and
RESV did not alter SIRT1 mRNA expression (Fig. S4). This
result is in line with the findings of other groups, where the
treatment with SRT1720 did not increase SIRT1 expression but
caused metabolic effects that required SIRT1 activity (71, 76).
Our results showed that the exposure to SRT1720 decreased
HAS2 expression both at the mRNA and protein levels,
although the reduction on HAS2 protein was not as efficient as
the reduction of HAS2 transcript (probably due to post-trans-
lational modifications that alter HAS2 expression and enzy-
matic activity (77)). However, the selective silencing of SIRT1
increased HAS2 mRNA and protein levels. Interestingly, the
treatment with RESV inhibited HAS2 mRNA but not the pro-
tein production, suggesting that SIRT1 may have different
effects onHAS2 protein. Indeed, SRT1720 and RESV are struc-
turally unrelated, and SRT1720 is hundreds of times more effi-
cient than RESV to activate SIRT1 (78). Moreover, the activa-
tion of SIRT1 by SRT1720 and RESV reduced the amount of
pericellularHA, suggesting that SIRT1 could be able to regulate
Figure 6. SIRT1 activators affect HAS2–AS1 expression and NF-B
nuclear translocation. A, quantitative RT-PCR analyses are shown for HAS2–
AS1 expression in AoSMCs treated for 24 h with 0.1 g/ml TNF alone or with
1 M SRT1720 or 100 M RESV. Data are expressed as relative expression of
HAS2–AS1 with respect to its control (CNTR). Values are reported as mean
S.E. of three independent experiments performed in duplicates. *, p0.05; **,
p  0.01; ***, p  0.001. B, quantitative RT-PCR analyses are shown for
AoSMCs nucleofected with 50 nM scrambled siRNA or HAS2 siRNA and left
untreated or treated with 0.1 g/ml TNF for 24 h. Data are shown as mean
S.E. of three independent experiments. *, p 0.05; **, p 0.01. C, represen-
tative images are shown for AoSMCs nucleofected with 4 g of
pcDNA3-GFP-RelA plasmid and grown on coverslips. Twenty four hours after
the transfection, cells were treated as indicated for 24 h, washed in PBS, and
observed by confocal microscopy (63 objective). Bars, 20 m.
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HAS2 expression and hence HA production. As the ability of
vascular SMCs to migrate and proliferate to the intima is sus-
tained by pro-inflammatory cytokines (79), we treatedAoSMCs
with TNF tomimic a pro-inflammatorymicroenvironment in
vitro.
Our data demonstrate that treatment with TNF alone
induced AoSMC migration, increased the adhesion of mono-
cytes to the pericellular HA, and stimulated HAS2 production.
The changes observed in cell motility are supported by the
modulation of RHAMM, the HA receptor that specifically reg-
ulates vascular SMCmigration (59). The up-regulation ofTSG6
upon TNF exposure could explain the formation of an
HC–HA-enriched pericellular coat that is adhesive for mono-
cytes. Interestingly, SRT1720 and RESV counteracted the
TNF effects, reducing RHAMM expression and AoSMC
motility, as well as the levels of TSG6 and monocyte adhesion.
The stimulation with TNF without or with SRT1720 or
RESVdid not influenceAoSMCproliferation and viability. This
result is in line with the lack of CD44 modulation, as CD44
is one of the main regulators of vascular SMC proliferation
(60, 80).
All these data strongly support the hypothesis that HA is one
of the main players to trigger SMC motility and to induce
immune cell recruitment. SIRT1 activation, through the inhi-
bition of HAmetabolism, can reduce the effects of a proinflam-
matory microenvironment on vascular cells in vitro.
To investigate the mechanism that allows the regulation of
HAS2 by SIRT1, we examined the antagonistic cross-talk
between SIRT1 and NF-B. NF-B is the major transcription
factor that mediates TNF-induced inflammatory responses
through the nuclear translocation of its subunit p65. It is known
that SIRT1mediates deacetylation of p65 thereby preventing its
translocation into the nucleus, even upon the stimulation with
RESV or SRT1720 (81–83). Moreover, the acetylation/deacety-
lation balance is important to regulate nuclear trafficking.
Indeed, some sirtuins (i.e. SIRT7 and SIRT2) can control the
nuclear export ofNF-Bby deacetylating the smallGTPaseRan
(84, 85). Alternatively, modifications in NF-B shuttling could
be due to an impairment of the nuclear transport proteins, such
as importin 5 (86). Although we did not investigate the acety-
lation status of p65, our results revealed that the treatment with
TNF stimulated p65 nuclear translocation in AoSMCs,
whereas the activation of SIRT1 retained p65 in the cytoplasm,
confirming the inhibitory effect of SIRT1on theTNF-induced
inflammatory response.
Previous studies revealed the presence of NF-B–binding
sites on the HAS2–AS1 promoter (33, 87), which could explain
the increase of HAS2–AS1 mRNA levels after TNF stimula-
tion. According to our working model (Fig. 8), the pro-inflam-
matory stimulus of TNF causes p65 nuclear translocation and
the subsequent activation of the HAS2–AS1 promoter, which
in turn stimulates HAS2 expression. In contrast, the activation
of SIRT1 by SRT1720 and RESV (although at different extents)
inhibited p65 nuclear translocation, HAS2–AS1 promoter acti-
vation, and thereforeHAS2 expression. AsHAS2–AS1 has spe-
cific effects on chromatin structure around theHAS2 promoter
(32), it is not surprising that all the treatments have strong
effects on HAS2 rather than on HAS3 expression. HAS2–AS1
exhibited a coordinated expression with HAS2 as already dem-
onstrated byMichael et al. (87). To confirm the proposed path-
Figure7.NF-Bblockade influencesHAS2–AS1expression.A, confocal microscopy images are shown for AoSMCs seeded on coverslips, nucleofected with
4 g of pcDNA3-GFP-RelA, and treated with 0.1 g/ml TNF alone or in combination with 10 M PDTC (63 objective). Bars, 20 M. Quantitative RT-PCR
analyses are shown for HAS2–AS1 (B) and HAS2 (C) expression of AoSMCs treated with 0.1 g/ml TNF alone or with 10 M PDTC for 24 h. Data are displayed
as mean S.E. of three independent experiments. *, p 0.05; **, p 0.01; ***, p 0.001; CNTR, control.
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way, the HAS2 silencing did not influence HAS2–AS1 expres-
sion or NF-B localization, whereas the inhibition of NF-B
nuclear translocation prevented both HAS2–AS1 and HAS2
expression in proinflammatory conditions. Therefore, our data
support the hypothesis that SIRT1 regulates HAS2 expression
via NF-B and HAS2–AS1.
The partnership between SIRT1 and AMPK is longstanding.
AMPK is the main ATP/AMP sensor in mammalian cells acti-
vated during calorie restriction and energy stress status. In the
literature there are many papers describing that AMPK can
function as a SIRT1 activator and that, mutually, SIRT1 is
required for AMPK activation (72, 88). The anabolic pathway
related to HA synthesis is a high-energy–demanding process,
and it is allowed only when all the cellular energetic require-
ments are satisfied. Indeed, in vitro experiments with AoSMCs
demonstrated that HAS2 activity and, subsequently, HA pro-
duction can be inhibited by AMPK through the phosphoryla-
tion of HAS2 Thr-110 (89).
Because SIRT1 can function both in the nucleus and in the
cytoplasm, the deacetylase activity of SIRT1 can also be
addressed to HAS2 protein itself or to the histones regulating
chromatin accessibility to the HAS2 promoter. In conclusion,
the effects of SIRT1 on HAS2 regulations are widespread and
can be the result of a synergic activity of SIRT1, which could act
at the nuclear level controlling p65 deacetylation or chromatin
accessibility after histonemodifications or at cytoplasmic levels
activating AMPK or de-acetylating HAS2 protein.
Experimental procedures
Cell cultures and treatments
Primary human AoSMCs were purchased from Lonza,
grown for 5–8 passages in SMGM2 culture medium supple-
mentedwith 5%FBS, andmaintained at 37 °C in the presence of
5%CO2. Briefly, 1.2 105 cells were plated in a 35-mmdish and
incubated for 24 h with DMEM (Euroclone) containing 0.2%
FBS to induce starvation. After 24 h, DMEMwas replaced with
complete medium, and cells were treated for 24 h with 1 M
SRT1720 (Selleck Chemicals), 100 M RESV (Selleck Chemi-
cals), and/or with 0.1 g/ml TNF (Abnova) to induce the
inflammatory responses. To inhibit p65 nuclear translocation,
cells were treatedwith 10M ammoniumpyrrolidinedithiocar-
bamate (PDTC, Sigma) for 24 h.
Gene expression determinations by quantitative RT-PCR
Total RNA was isolated from AoSMCs with the PureLinkTM
RNAmini kit (Invitrogen), retrotranscribed using the high-ca-
pacity cDNA synthesis kit (Applied Biosystems), and amplified
with an ABI Prism 7000 instrument (Applied Biosystems). The
following human TaqMan gene expression assays were used:
HAS1 (Hs00155410_m1); HAS2 (Hs00193435_m1); HAS3
(Hs00193436_m1); HAS2–AS1 (Hs03309447_m1); SIRT1
(Hs01009006_m1); CD44 (Hs01075861_m1); RHAMM
(Hs00234864_m1); TSG6 (Hs00200178_m1); and -actin
(Hs99999903_m1). The relative gene expressions were
determined by 2Ct method (90).
Cell transfection
To knock down SIRT1 expression, 8  105 AoSMCs were
transiently nucleofected using a Nucleofector Apparatus
(Amaxa) and the human AoSMC nucleofection kit (Lonza)
with 100 nM SIRT1 siRNA (Silencer Select SIRT1, Ambion) or a
scrambled siRNA (silencer negative control 1, Ambion).
The same nucleofection kit was used to silence HASes
expressions using 50 nM siRNAs againstHAS1 (Silencer Select
HAS1, Ambion), HAS2 (Silencer Select Pre-Designed HAS2,
Ambion), and HAS3 (Silencer Select HAS3, Ambion). To
study GFP–p65 subcellular localization 4 g of pcDNA3-
GFP-RELA plasmid (23255, Addgene) was nuclefected in
AoSMCs.
HA determination
To quantify the amount of HA produced by AoSMCs, cell
culture media were collected 24 h after the treatments and
diluted 1:100. The quantification of HAwas done with the hya-
luronan quantikine ELISA kit (R&D Systems) according to the
manufacturer’s instructions.
The analysis of HA and CS-0S was done by PAGEFS, as
described previously (48). Briefly, AoSMC culture mediumwas
digested with 10 milliunits/ml proteinase K (Fynnzymes), and
the glycosaminoglycans were purified by ethanol precipitation.
The specific unsaturated disaccharides of HA (HA) and CS
were obtained by specific glycosidase digestions, derivatized
with 2-aminoacridone, and separated by gel electrophoresis.
To evaluate the pericellular coat of HA, a particle exclusion
assay was used (91, 92). Briefly, 1.5 103 cells were seeded in a
12-well plate and treatedwith 1MSRT1720 and 100MRESV.
After 24 h, 1.5 107 fixed human red blood cells were added to
eachwell. After an incubation time of 30min at 37 °C, cells were
examined by contrast microscopy, and 10 pictures per well
were taken. As a control, cells were treated with 2 units/ml
Streptomyces hyalurolyticus HYAL (Sigma). The analysis of the
images and the relative quantification were done using the
image analysis software ImageJ.
Figure 8. Working model for protective effects of SIRT1 via HAS2–AS1
andNF-B. Stimulation of AoSMCs with TNF can activate the p65 subunit of
NF-B through acetylation with its consequent translocation into the nucleus
and the activation of target genes involved in the inflammatory response. In
the nucleus, p65 is able to activate HAS2–AS1 promoter, which induces HAS2
expression and subsequent synthesis of a monocyte adhesive extracellular
HA matrix on AoSMCs. The activation of SIRT1 by SRT1720 and RESV initiates
the inhibition pathway (red) by retaining p65 in the cytoplasm, probably by
promoting deacetylation of p65, which prevents p65 nuclear translocation
that prevents activation of an HAS2–AS1 promoter. This would inhibit HAS2
mRNA and protein expression, thereby preventing formation of the mono-
cyte adhesive HA matrix, immune cells recruitment, and AoSMC migration,
thus protecting AoSMCs from TNF-induced inflammation.
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Western blotting
Proteins were collected from treated or untreated AoSMCs
by using RIPA buffer supplementedwith 10% of protease inhib-
itors (Sigma) and separated on precast 4–12% gradient acryl-
amide gels (Genscript) at 120 V in 1Mops Buffer (Genscript).
Protein samples were transferred to nitrocellulose membrane
at 250 mA for 1 h at 4 °C, blocked in 5% BSA, 0.1% TBS-Tween
20 for 1 h, and incubated with primary antibody overnight at
4 °C. After extensive washing, the membranes were incubated
with primary antibody and with horseradish peroxidase–
conjugated secondary antibody. Chemiluminescence was de-
tected using the LiteAblot turbo chemiluminescent substrate
(Euroclone), and bands were revealed using the LI-COR Odys-
sey IR imaging system (LI-COR Biosciences). Western blot-
ting experiments were done using antibodies against HAS2
(polyclonal Y14, sc34068, Santa Cruz Biotechnology), GAPDH
(polyclonal V18, sc20357, Santa Cruz Biotechnology), and
-tubulin (monoclonal 11H10, Cell Signaling).
Monocyte adhesion assay
Adhesion of U937 monocytes to AoSMC cultures was done
as described previously (89, 93). Briefly, 1  106 U937 mono-
cytes were resuspended in complete medium, plated on
untreated or treated AoSMCs, and incubated for 1 h at room
temperature. Subsequently, cells were washed three times with
their appropriatemedium, and the evaluation of adherentU937
cells was detected by microscopy, counting the number of
adherent monocytes in 10 independent fields. To verify that
U937 binding was specific to HA, AoSMCs were treated with 2
units/ml of S. hyalurolyticus HYAL (Sigma) for 1 h at 37 °C.
Migration assay
AoSMC migration was determined by a scratch assay (94).
Briefly, 1.8 105 cells were plated in a 35-mm dish and serum-
deprived (0.2% FBS) for 24 h. Three scratches per well were
done with a 20-l pipette tip, and new complete medium was
added with 0.1g/ml TNF alone or in combination with 1M
SRT1720 or 100 M RESV. Pictures were taken through light
microscopy at different time points (0, 3, 6, and 9 h) and ana-
lyzed using ImageJ software.
Cell proliferation assay (MTT)
To study cell proliferation, 5 103AoSMCswere seeded in a
96-well plate and incubated for 24 h with DMEM 0.2% FBS.
After 24 h,AoSMCswere treatedwith 0.1g/mlTNF alone or
with 1 M SRT1720 or 100 M. At the end of the treatment (24
h), the medium was replaced with 200 l of fresh SMGM2 cul-
ture medium supplemented with 50 l of 5 mg/ml MTT and
incubated at 37 °C for 5 h. The reactionwas stopped adding 200
l of DMSO and 25 l of Sorensen glycine buffer per well. The
plate was read at 570 nm.
Evaluation of NF-B nuclear translocation
AoSMCs were nucleofected with the plasmid pcDNA3-
GFP-RELA (Addgene) coding for the GFP–p65 protein fusion,
plated on poly-L-lysine (100 ng/liter) pre-coated glass cover-
slips (35mm in diameter), and treated with 0.1 MTNF alone
or in combination with 1 M SRT1720, 100 M RESV, or 10 M
PDTC (Sigma). After 48 h, cell culture medium was removed,
and AoSMCs were washed three times with PBS and fixed with
a 4% paraformaldehyde/PBS solution for 10 min at room tem-
perature. Coverslipsweremounted on glass slides, and p65 sub-
cellular localizationwas analyzed by confocalmicroscopy using
a Leica TCS SP5 instrument.
Statistical analysis
All data are expressed as mean S.E. Statistical significance
was calculated with Student’s t test for unpaired data or one-
way ANOVA followed by Bonferroni post hoc test. For the
migration assays, two-way ANOVA followed by Bonferroni
post hoc test analysis were performed. All statistical tests were
carried out usingGraphPad Prism (GraphPad software, version
5.3, San Diego, CA). All experiments were repeated at least
three times (figure legends report the exact number of repli-
cates of each experiments).
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